Skyworth Group Ltd
Change company Symbol lookup
Select an option...
SWDHY Skyworth Group Ltd
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
Go


Based in Hong Kong
Company profile

Skyworth Group Limited, formerly Skyworth Digital Holdings Limited is an investment holding company. The Company is principally engaged in the manufacture and sale of consumer electronic products and upstream accessories, property holding and property holding. The Company operates in six segments: television (TV) products, TV products, digital set-top boxes, liquid crystal display (LCD) modules, white appliances and property holding. Its two TV products segments are engaged in the design, manufacture and sale of televisions for the People's Republic of China (PRC) market and overseas markets. Its digital set-top boxes segment, liquid crystal display (LCD) modules segment and white appliances segment are engaged in the design, manufacture and sale of digital set-top boxes, LCD modules and white appliances, including refrigerators, washing machines and others. Its property holding segment engages in the leasing of properties.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$16.30
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

SESN 4-DAY DEADLINE ALERT: Hagens Berman Alerts Sesen Bio (SESN) Investors to OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm's Attorneys Now

10:06 am ET October 14, 2021 (Globe Newswire) Print

Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now.

Class Period: Dec. 21, 2020 - Aug. 17, 2021

Lead Plaintiff Deadline: Oct. 18, 2021

Visit: www.hbsslaw.com/investor-fraud/SESN

Contact An Attorney Now: SESN@hbsslaw.com

844-916-0895

Sesen Bio, Inc. (SESN) Securities Fraud Class Action:

The complaint alleges that Defendants misrepresented clinical trial data for Sesen's lead product candidate Vicineum for the treatment of certain non-muscle invasive bladder cancer.

Specifically, Defendants concealed that: (1) the company's clinical trial for Vicineum had more than 2,000 protocol violations, including 215 classified as "major," (2) three of the company's clinical investigators were found guilty of "serious noncompliance," including backdating data, (3) the company submitted tainted data for Vicineum to the FDA, (4) the company's clinical trials showed that Vicineum leaked out into the body and caused serious side effects and increased risks for fatal liver injury.

The truth began to emerge on Aug. 13, 2021, when Sesen announced the FDA did not approve the BLA in its present form and sought additional clinical/statistical data.

Then, on Aug. 16, 2021, the company revealed it needed to conduct an additional clinical trial to provide the FDA with additional efficacy and safety data.

Finally, on Aug. 18, 2021, STAT published an article entitled "Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show." STAT cited hundreds of pages of internal documents and three people familiar with the matter reported the Vicineum clinical trial "was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose."

These events sent the price of Sesen shares sharply lower.

"We're focused on investors' losses and proving Sesen lied to them about the prospects for Vicineum," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Sesen and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sesen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SESN@hbsslaw.com.

About Hagens Berman

Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

https://ml.globenewswire.com/media/51670c91-d369-4a8c-8102-d393de9f6d19/small/download-jpg.jpg

https://ml.globenewswire.com/media/51670c91-d369-4a8c-8102-d393de9f6d19/small/download-jpg.jpg

comtex tracking

COMTEX_395190430/2010/2021-10-14T10:06:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.